3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Other hematologic neoplasm
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasm Metastasis
2
Melanoma
2
Lung Neoplasms
2
Breast Neoplasms
2
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma
1
Prostatic Neoplasms
1
Neoplasms
1
Liver Neoplasms
1
Leukemia
1
Kidney Neoplasms
1
Glioblastoma
1
Esophageal Neoplasms
1
Disease
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Bronchogenic
1
Interventions
pembrolizumab
26
Nivolumab
10
Docetaxel
8
avelumab
7
atezolizumab
7
Gemcitabine
7
Carboplatin
6
Trastuzumab
5
Ipilimumab
5
Radiosurgery
4
Psychiatric Rehabilitation
4
Immunoglobulin G
4
Early Intervention, Educational
4
Cyclophosphamide
4
fludarabine
3
durvalumab
3
cemiplimab
3
Taxes
3
Radiotherapy
3
Polymerase Chain Reaction
3
Gene Expression Profiling
3
Disulfides
3
Counseling
3
Cisplatin
3
Blood Specimen Collection
3
Biopsy
3
Albumin-Bound Paclitaxel
3
130-nm albumin-bound paclitaxel
3
zimberelimab
2
utomilumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Urinary Bladder Neoplasms
×
Interleukin-15
×
Thoracic
×
Clear all
NCT07410676
2026-02-18
EBNK-ST-001
Essen Biotech
Phase 1/2
Recruiting
83 enrolled